591 related articles for article (PubMed ID: 27540379)
1. Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis.
Lovelace MD; Varney B; Sundaram G; Franco NF; Ng ML; Pai S; Lim CK; Guillemin GJ; Brew BJ
Front Immunol; 2016; 7():246. PubMed ID: 27540379
[TBL] [Abstract][Full Text] [Related]
2. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases.
Lovelace MD; Varney B; Sundaram G; Lennon MJ; Lim CK; Jacobs K; Guillemin GJ; Brew BJ
Neuropharmacology; 2017 Jan; 112(Pt B):373-388. PubMed ID: 26995730
[TBL] [Abstract][Full Text] [Related]
3. Involvement of the kynurenine pathway in human glioma pathophysiology.
Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ
PLoS One; 2014; 9(11):e112945. PubMed ID: 25415278
[TBL] [Abstract][Full Text] [Related]
4. Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Mohamadkhani A; Klegeris A; McElhinney A; Mafi Z; Hajiesmaeili M; Sayehmiri F
Front Immunol; 2022; 13():1013784. PubMed ID: 36426364
[TBL] [Abstract][Full Text] [Related]
5. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
Mazarei G; Budac DP; Lu G; Lee H; Möller T; Leavitt BR
Exp Neurol; 2013 Nov; 249():144-8. PubMed ID: 23994717
[TBL] [Abstract][Full Text] [Related]
6. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
Fujigaki H; Yamamoto Y; Saito K
Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease.
Mazarei G; Leavitt BR
J Huntingtons Dis; 2015; 4(2):109-18. PubMed ID: 26397892
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease.
Lim CK; Fernández-Gomez FJ; Braidy N; Estrada C; Costa C; Costa S; Bessede A; Fernandez-Villalba E; Zinger A; Herrero MT; Guillemin GJ
Prog Neurobiol; 2017 Aug; 155():76-95. PubMed ID: 27072742
[TBL] [Abstract][Full Text] [Related]
9. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
10. Kynurenine pathway in Parkinson's disease-An update.
Venkatesan D; Iyer M; Narayanasamy A; Siva K; Vellingiri B
eNeurologicalSci; 2020 Dec; 21():100270. PubMed ID: 33134567
[TBL] [Abstract][Full Text] [Related]
11. Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects.
Badawy AA
Int J Tryptophan Res; 2017; 10():1178646917691938. PubMed ID: 28469468
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in clinical trials targeting the kynurenine pathway.
Pires AS; Sundaram G; Heng B; Krishnamurthy S; Brew BJ; Guillemin GJ
Pharmacol Ther; 2022 Aug; 236():108055. PubMed ID: 34929198
[TBL] [Abstract][Full Text] [Related]
13. The kynurenine pathway in brain tumor pathogenesis.
Adams S; Braidy N; Bessede A; Brew BJ; Grant R; Teo C; Guillemin GJ
Cancer Res; 2012 Nov; 72(22):5649-57. PubMed ID: 23144293
[TBL] [Abstract][Full Text] [Related]
14. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.
Mazarei G; Budac DP; Lu G; Adomat H; Tomlinson Guns ES; Möller T; Leavitt BR
J Neurochem; 2013 Dec; 127(6):852-67. PubMed ID: 23786539
[TBL] [Abstract][Full Text] [Related]
15. Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression.
Watzlawik JO; Wootla B; Rodriguez M
Curr Pharm Des; 2016; 22(8):1049-59. PubMed ID: 26899126
[TBL] [Abstract][Full Text] [Related]
16. Kynurenine pathway modulation reverses the experimental autoimmune encephalomyelitis mouse disease progression.
Sundaram G; Lim CK; Brew BJ; Guillemin GJ
J Neuroinflammation; 2020 Jun; 17(1):176. PubMed ID: 32505212
[TBL] [Abstract][Full Text] [Related]
17. Overview of the role of vitamins and minerals on the kynurenine pathway in health and disease.
Majewski M; Kozlowska A; Thoene M; Lepiarczyk E; Grzegorzewski WJ
J Physiol Pharmacol; 2016 Feb; 67(1):3-19. PubMed ID: 27010891
[TBL] [Abstract][Full Text] [Related]
18. IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment.
Guillemin GJ; Kerr SJ; Pemberton LA; Smith DG; Smythe GA; Armati PJ; Brew BJ
J Interferon Cytokine Res; 2001 Dec; 21(12):1097-101. PubMed ID: 11798468
[TBL] [Abstract][Full Text] [Related]
19. The kynurenine pathway and neurodegenerative disease.
Maddison DC; Giorgini F
Semin Cell Dev Biol; 2015 Apr; 40():134-41. PubMed ID: 25773161
[TBL] [Abstract][Full Text] [Related]
20. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons.
Guillemin GJ; Smythe G; Takikawa O; Brew BJ
Glia; 2005 Jan; 49(1):15-23. PubMed ID: 15390107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
